Rakuten Investment Management Inc. Makes New Investment in Cencora, Inc. $COR

Rakuten Investment Management Inc. acquired a new stake in shares of Cencora, Inc. (NYSE:COR) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 33,862 shares of the company’s stock, valued at approximately $10,416,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Elevation Wealth Partners LLC increased its position in shares of Cencora by 506.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 97 shares of the company’s stock worth $27,000 after purchasing an additional 81 shares in the last quarter. Bell Investment Advisors Inc bought a new position in Cencora during the 2nd quarter valued at about $28,000. Caitlin John LLC bought a new position in Cencora during the 2nd quarter valued at about $28,000. Cassaday & Co Wealth Management LLC acquired a new position in Cencora in the first quarter valued at about $35,000. Finally, Lynch Investment Planning LLC acquired a new position in Cencora in the third quarter valued at about $39,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Performance

Cencora stock opened at $339.58 on Friday. The stock has a 50-day simple moving average of $324.83 and a 200 day simple moving average of $317.36. The company has a quick ratio of 0.58, a current ratio of 0.94 and a debt-to-equity ratio of 3.01. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The stock has a market capitalization of $64.80 billion, a price-to-earnings ratio of 18.95, a P/E/G ratio of 1.84 and a beta of 0.58.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $4.66 EPS for the quarter, topping analysts’ consensus estimates of $4.58 by $0.08. Cencora had a net margin of 1.03% and a return on equity of 110.72%. The firm had revenue of $88.35 billion for the quarter, compared to analyst estimates of $87.95 billion. During the same quarter in the prior year, the firm earned $3.84 EPS. The company’s revenue was up 5.5% on a year-over-year basis. On average, research analysts anticipate that Cencora, Inc. will post 19.53 earnings per share for the current fiscal year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 30th. Shareholders of record on Friday, November 13th will be paid a $0.66 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.60. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, November 13th. Cencora’s payout ratio is presently 14.73%.

Key Stories Impacting Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora reported fiscal Q4 adjusted EPS of $4.66, above the $4.58 consensus, while revenue of $88.35 billion also topped expectations and grew 5.5% year over year. Fiscal 2026 results
• Positive Sentiment: Management forecast fiscal 2027 adjusted EPS of $19.40–$19.75, signaling continued earnings growth. Specialty-drug demand was a key contributor to results. Fiscal 2027 outlook
• Positive Sentiment: Leerink Partners raised its price target to $405 and maintained an “outperform” rating. Cencora also increased its quarterly dividend 10%, to $0.66 per share. Cencora earnings coverage
• Neutral Sentiment: Cencora is reorganizing its reporting into two segments to sharpen focus and visibility. The change may help investors assess performance, but its effect on execution remains to be seen. Organizational changes
• Negative Sentiment: Reports linked the share weakness to Cardinal Health’s earnings beat, which may have shifted investor attention toward the competitor’s results. Cencora and Cardinal Health shares

Insider Activity

In other news, EVP Elizabeth Campbell sold 11,300 shares of the company’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the transaction, the executive vice president directly owned 19,455 shares in the company, valued at approximately $6,305,754.60. This represents a 36.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.38% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on COR. Wells Fargo & Company upped their price objective on shares of Cencora from $331.00 to $395.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 11th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $330.00 target price on shares of Cencora in a research note on Tuesday, September 8th. Argus lifted their target price on shares of Cencora from $340.00 to $380.00 and gave the company a “buy” rating in a research note on Tuesday, October 20th. Morgan Stanley boosted their target price on Cencora from $346.00 to $377.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Finally, UBS Group decreased their price target on Cencora from $430.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, October 16th. Thirteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and a consensus target price of $368.73.

About Cencora

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.